Also known as: With DAC, or without DAC (Mod GRF 1-29)
A modified GHRH analog that raises growth hormone and IGF-1. Comes in a long-acting (DAC) and short-acting form.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Binds the GHRH receptor on the pituitary. The DAC version binds albumin in blood, so a single shot keeps GH elevated for about a week.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Muscle & growth hormone | C | Limited human data, case series or practitioner reports |
| Fat loss & weight | C | Limited human data, case series or practitioner reports |
| Sleep | C | Limited human data, case series or practitioner reports |
| Injury & tissue repair | C | Limited human data, case series or practitioner reports |
At a glance
- Route
- Subcutaneous
- Half-life
- With DAC: 6 to 8 days. Without DAC: about 30 minutes
Reported dosing
With DAC: 1 to 2 mg once weekly (practitioner reports). Without DAC: 100 mcg 1 to 3 times daily, usually with a GHRP.
Timing: Without DAC: fasted, at least 2 hours after eating, often before bed. With DAC: same day weekly.
Cycle: Commonly 8 to 12 weeks on, then 4 weeks off.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Flushing, headache, injection-site reactions
- Water retention, numbness or tingling in hands
- Raised blood sugar
Who should avoid it
- Active cancer
- Pregnancy
- Uncontrolled diabetes
Often combined with
Very commonly combined with ipamorelin (same syringe, without DAC) for a stronger GH pulse.
Key findings
One human study (JCEM 2006): a single dose raised GH 2 to 10 fold for 6+ days and IGF-1 1.5 to 3 fold. Clinical development stopped after Phase 2.
2026 update
Clinical development stopped in 2006 after a trial participant died; the cause was not established.
Where it is legal (Oct 2026)
| US | Not approved |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open CJC-1295 in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.